Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay Lucidarme

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
Emerging Infectious Diseases|January 27, 2016
Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, EnglandShamez N Ladhani, Marzia Monica Giuliani, Alessia Biolchi, et al.
Clinical and Vaccine Immunology : CVI|December 3, 2010
Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBPJay Lucidarme, Lynne S Newbold, Jamie Findlow, et al.
Plos One|February 12, 2019
Viable Neisseria meningitidis is commonly present in saliva in healthy young adults: Non-invasive sampling and enhanced sensitivity of detection in a follow-up carriage study in Portuguese studentsFernanda Rodrigues, Hannah Christensen, Begonia Morales-Aza, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 4, 2025
Impact of molecular point-of-care testing on surveillance and public health management of invasive meningococcal diseaseEmma J Heymer, Stephen A Clark, Helen Campbell, et al.
Vaccine|February 21, 2025
Nanoparticles displaying fHbp elicit an enhanced antibody response against meningococcal B isolates compared to low valency fHbp antigensJulia L McKechnie, Elizabeth Kepl, Jennifer Louth, et al.
Vaccine|August 20, 2013
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverageGiacomo Frosi, Alessia Biolchi, Morena Lo Sapio, et al.
The Lancet. Child & Adolescent Health|December 9, 2021
Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling studyHelen Campbell, Nick Andrews, Sydel R Parikh, et al.
The New England Journal of Medicine|January 24, 2020
Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in EnglandShamez N Ladhani, Nick Andrews, Sydel R Parikh, et al.
Plos One|March 3, 2010
The influence of IS1301 in the capsule biosynthesis locus on meningococcal carriage and diseaseElisabeth Kugelberg, Bridget Gollan, Christopher Farrance, et al.
Emerging Infectious Diseases|January 21, 2012
Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009Shamez N Ladhani, Jay Lucidarme, Lynne S Newbold, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Emerging Infectious Diseases|January 27, 2016
Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, EnglandShamez N Ladhani, Marzia Monica Giuliani, Alessia Biolchi, et al.
Clinical and Vaccine Immunology : CVI|December 3, 2010
Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBPJay Lucidarme, Lynne S Newbold, Jamie Findlow, et al.
Plos One|February 12, 2019
Viable Neisseria meningitidis is commonly present in saliva in healthy young adults: Non-invasive sampling and enhanced sensitivity of detection in a follow-up carriage study in Portuguese studentsFernanda Rodrigues, Hannah Christensen, Begonia Morales-Aza, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 4, 2025
Impact of molecular point-of-care testing on surveillance and public health management of invasive meningococcal diseaseEmma J Heymer, Stephen A Clark, Helen Campbell, et al.
Vaccine|February 21, 2025
Nanoparticles displaying fHbp elicit an enhanced antibody response against meningococcal B isolates compared to low valency fHbp antigensJulia L McKechnie, Elizabeth Kepl, Jennifer Louth, et al.
Vaccine|August 20, 2013
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverageGiacomo Frosi, Alessia Biolchi, Morena Lo Sapio, et al.
The Lancet. Child & Adolescent Health|December 9, 2021
Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling studyHelen Campbell, Nick Andrews, Sydel R Parikh, et al.
The New England Journal of Medicine|January 24, 2020
Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in EnglandShamez N Ladhani, Nick Andrews, Sydel R Parikh, et al.
Plos One|March 3, 2010
The influence of IS1301 in the capsule biosynthesis locus on meningococcal carriage and diseaseElisabeth Kugelberg, Bridget Gollan, Christopher Farrance, et al.
Emerging Infectious Diseases|January 21, 2012
Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009Shamez N Ladhani, Jay Lucidarme, Lynne S Newbold, et al.
Pageof 9